Since the discovery of the potential role of RUNX3 in gastric cancer, RUNX3 has been found to be inactivated in various cancers, including colorectal, liver, lung, prostate, and breast as well as gliomas [12–15, 17, 18, 21, 33–35]. This evidence concerns the gene RUNX3 and glioma.